[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. - Wikidata - wikimedia - TriplyDB

[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.

[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.

http://www.wikidata.org/entity/Q39972078

about

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas PET and MR imaging: the odd couple or a match made in heaven?Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies Staged lengthening arthroplasty for pediatric osteosarcoma around the knee.Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring.Imaging pediatric bone sarcomas.Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.Prognostic markers in osteosarcoma.18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.Clinical applications of positron emission tomography in sarcoma management.Pediatric oncology and the future of oncological imaging.Peritoneal sarcomatosis in pediatric malignancies.The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma.Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values.Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting.¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas.18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors.Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.

P2860

Q26825000-40CA9908-36D0-4B66-80DE-A06A9D131E63 Q26851721-D2F37774-AC45-483F-9985-2862685C9602 Q33434899-E0C37013-6B70-494C-9F91-AE5F073AF184 Q33559468-86259E2C-11B9-420A-AD22-85884555F65E Q33833813-15F472D4-447E-46A3-8A39-8EB869EA5848 Q34023973-86410222-68C6-4E33-8BAF-F87B112C3CDD Q34348226-AB8D31FE-F9D9-4465-9E47-D08E210AB614 Q34628840-458918DB-8208-41CB-9A65-A542E08EA045 Q35769381-CE4B131E-0789-4566-B052-A0FE5629C397 Q35848410-DC877445-0954-4A10-8B9C-9D97D2D3645F Q36335296-B340ECB5-E90B-4795-BC49-DAE34BAE5418 Q36499007-15205FEB-6102-4D96-86CD-0BB0D7B1DBA8 Q36750627-982A0F2E-74A4-4415-8AF2-5BA2576437CE Q37519308-3F78927F-00DE-4B6E-BAD7-7A6454D2283D Q37523470-21D3D1CF-02EC-4C05-AB2A-BB36E1D8FB99 Q37560522-0AFBAA14-8E61-4BD0-B88D-227414807D64 Q37621398-60C4D971-894A-4432-81E4-C6DBD4BB39C7 Q37687395-9A13DEE1-1807-427A-822D-13EA208282B6 Q37836534-1A88B219-6F90-491F-B1A2-16921BE24D28 Q37845828-439030E9-3AD2-4CA3-A35A-17BEDE7ACA78 Q37869417-3450D905-D8BC-40E8-B18E-869CDE7888D8 Q38045850-77D8552D-B624-4035-BC66-19D332A219DF Q38046209-72ED9035-B023-4E85-BD77-027D9B91B328 Q38217056-9B5B3A46-3935-4D01-80A6-F8E9C3F33111 Q41594930-FDA6DA6D-1335-46F4-BC12-620C0D0FD631 Q43529305-8CAA47B5-7314-4237-806F-F0AF9BF0D448 Q44090756-ADA3B1D2-C1C4-4AAF-9968-E5696DE1A3A5 Q44406732-A3CDCDFE-99B3-4845-80E5-0EDA73AA3C3F Q44442401-70061A1C-A3FB-4435-A2E7-FBB8D476B42F Q53150564-F1BE3D32-550E-4430-B5E0-4DAB7434E8E3 Q53187964-A57F05AA-8098-4231-9139-0FC15F5B0AD2 Q53404618-35D03660-2160-4E7B-B34E-B652D047C714

P2860

[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.

http://www.wikidata.org/entity/Q39972078

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.

@en

[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.

@nl

type

label

[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.

@en

[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.

@nl

prefLabel

[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.

@en

[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.

@nl

P1433

Q39972078-9E0651E0-8DAA-45AD-9416-81ABDA54AA92

P1476

Q39972078-2BD685AA-8977-4AA1-88CA-197601F11DE3

P2093

Q39972078-14946898-CA99-43A3-B93D-53974C0C2AEC

Q39972078-592A2451-1735-4448-997F-FE4CAEC008E6

Q39972078-8621603E-6110-4766-8D64-BD4C4671E49E

Q39972078-D8C8F7A7-F1CB-47A9-AF80-0E8DC5FFCCA9

Q39972078-FF753F29-5328-4FBC-A02C-8C59509F9BAD

P2860

Q39972078-04557474-7C0F-40A4-BCC4-1B8F77D8C761

Q39972078-05C25253-0B75-4693-9A64-C52CE61B8AC2

Q39972078-1D19D6DB-C4AE-4940-A84A-7EE55E9A8BEB

Q39972078-335FFF58-6815-4A60-BDA3-2DEFC7ACA307

Q39972078-3D29BB9C-7EB8-46F6-BF7A-AD0D3A3F7AC0

Q39972078-44713068-1656-43C3-B43C-761174E34631

Q39972078-5D64CBD6-508F-4943-868F-1223D27E6D41

Q39972078-6CFA862D-F8E0-4C47-B91C-CF8C12B83E6D

Q39972078-7CB4D4FE-13F7-4F64-9513-E40E453D35FF

Q39972078-8ABA0C2E-025A-4953-A326-ED2F10761BEF

P304

Q39972078-BB9C22C0-E1BA-46BE-867C-A6AB621FD5F4

P31

Q39972078-B752231D-7607-4753-8021-57826FF4426F

P356

Q39972078-29106C47-5780-4750-8FEF-103C781E2C8B

P407

Q39972078-5054BBB5-8C5F-4A5B-B404-2D20EBC6DE55

P433

Q39972078-4F205D24-075C-4ACD-8D5D-79030D123306

P478

Q39972078-4CDC5377-160A-494C-B75C-F1B63D4CB4D0

P577

Q39972078-87F95694-D567-40CD-BFA3-F685F8D8FA08

P5875

Q39972078-F034ADE4-57D2-4992-A8CD-1E5E87B4A41B

P698

Q39972078-AD534150-4DEF-4466-AEBA-150C4DD242ED

P921

Q39972078-7DE40FD6-7D44-4823-A67B-8DDC1F301898

P932

Q39972078-9AA6F6F6-E11A-43C0-BFDF-FF522CC22FC5

P356

P1433

P1476

[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.

@en

P2093

Douglas S Hawkins

http://www.w3.org/2001/XMLSchema#string

Ernest U Conrad

http://www.w3.org/2001/XMLSchema#string

James E Butrynski

http://www.w3.org/2001/XMLSchema#string

Janet F Eary

http://www.w3.org/2001/XMLSchema#string

Scott M Schuetze

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.

Biology and therapeutic advances for pediatric osteosarcoma.

Imaging bone tumors in the 1990s.

Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery.

Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Prognostic factors in osteosarcoma: a critical review.

Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma.

P304

3519-3525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24421

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26283584

http://www.w3.org/2001/XMLSchema#string

P698

19517457

http://www.w3.org/2001/XMLSchema#string

P921

P932

2716419

http://www.w3.org/2001/XMLSchema#string